Literature DB >> 9885368

Circulating activated protein C in subjects with heterozygous Gln506-factor V.

J Petäjä1, L Hakala, V Rasi, J H Griffin.   

Abstract

Congenital resistance to activated protein C due to a point mutation in the factor V gene (Gln506-FV) is the most common genetic risk factor for familial venous thrombosis. Considering the central role of activated protein C as a physiological anticoagulant, the question of why the thrombotic risk associated with Gln506-FV was not more pronounced was asked. We hypothesized that in Gln506-FV heterozygotes, enhanced thrombin formation might preferentially activate protein C and thereby constitute a compensatory antithrombotic effect. We compared the circulatory level of activated protein C in twelve heterozygous carriers of Gln506-FV mutation with that in eighteen noncarriers in same families, and used prothrombin fragment 1+2 as a measure of thrombin generation. The circulating level of activated protein C was higher but not significantly different in heterozygotes compared with normal relatives. Activated protein C levels correlated strongly and positively with protein C antigen levels in both carriers (Spearman R 0.684, p < 0.05) and controls (Spearman R 0.642, p < 0.01). Correlation between activated protein C and prothrombin fragment 1+2 levels was of borderline significance (Spearman R 0.354, p = 0.055). In the current study, thrombin formation assessed by prothrombin fragment 1+2 levels was not significantly enhanced in subjects with heterozygous Gln506-FV compared with family members without the mutation. In conclusion, enhanced thrombin formation is not present in all healthy Gln506-FV heterozygotes in basal conditions. It seems that enhanced protein C activation by thrombin does not constitute a compensatory anticoagulant feedback loop in heterozygous carriers of Gln506-FV. However, the positive correlation between prothrombin fragment 1+2 and activated protein C suggests that, in healthy subjects and in basal conditions, thrombin upregulates the anticoagulant protein C pathway. Thus, it is questionable whether prothrombin fragment 1+2 can directly be used as an indicator of a hypercoagulable state.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9885368     DOI: 10.1159/000022381

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  2 in total

1.  Circulating activated protein C in thrombophilia carriers.

Authors:  Thijs E van Mens; Joost C M Meijers; Saskia Middeldorp
Journal:  J Thromb Thrombolysis       Date:  2017-04       Impact factor: 2.300

2.  Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis.

Authors:  Outi Lindstrom; Leena Kylanpaa; Panu Mentula; Pauli Puolakkainen; Esko Kemppainen; Reijo Haapiainen; Jose A Fernandez; John H Griffin; Heikki Repo; Jari Petaja
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.